Rocket Pharma is a fully integrated, clinical-stage company seeking gene therapy cures. They are advancing multiple gene therapies across a multi-platform pipeline of treatments that directly target the genetic mutation in the affected cells for rare, life-threatening disorders, including Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Danon Disease, Pyruvate Kinase Deficiency (PKD), and PKP2 arrhythmogenic cardiomyopathy (ACM).